Viewing Study NCT02122861

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 12:34 PM
Ignite Modification Date: 2026-02-25 @ 11:47 PM
Study NCT ID: NCT02122861
Status: COMPLETED
Last Update Posted: 2019-03-06
First Post: 2014-04-22
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
Sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma - Currently Enrolling View
None Non-small Cell Lung Cancer - Enrollment Completed View
None Sarcoma - Enrollment Completed View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Melanoma View